![](https://investorshub.advfn.com/uicon/440329.png?cb=1484301727)
Monday, January 24, 2022 5:09:54 AM
The Telegraph Newspaper today in the U.K.
Patients to receive new cancer drugs faster under Brexit rules shake-up
Seven medicines already approved as changes cut as much as a month off approval times
By
Hannah Boland
23 January 2022 • 6:00pm
Patients will receive new cancer drugs more quickly following post-Brexit changes to the regulatory oversight of pharmaceuticals.
The change of policy has already slashed approval times by as much as a month. The MHRA, Britain's regulator, has approved seven cancer treatments under the Project Orbis scheme, which it entered into last year after licensing decisions were no longer made by the European Medicines Agency.
Four of the newly approved treatments are for lung cancer and breast cancer. Another three are extensions of existing treatments.
Project Orbis links the UK to the US, Canada, Australia, Switzerland, Singapore and Brazil, harmonising the regulatory process so trial data can be submitted to all the regulators at the same time, where it can be reviewed and treatments approved.
Government officials have said the scheme is a Brexit benefit which will "speed up the time it takes to get these new medicines to patients".
European medical agency the EMA says it takes around a year for it to evaluate a medicine, after which it makes a recommendation to the European Commission, which can take another two months to approve.
The first drug the MHRA approved under Project Orbis last May - AstraZeneca's lung cancer treatment Tagrisso - took the EMA almost a month longer to approve.
AstraZeneca's executive vice president of oncology Dave Fredrickson praised Project Orbis as a "welcome initiative that has already shown it can help accelerate the speed of getting innovative cancer medicines to patients in the UK and across the globe".
He added: "It is vital for industry, regulators and health bodies to continue working closely together to make sure many more medicines can get to patients in the shortest possible time.”
The UK is among the countries facing a cancer treatment backlog as NHS resources have been diverted to tackling Covid, with experts saying it could take a decade to clear.
However, Project Orbis has attracted criticism from cancer specialists who warn that speeding up approvals risks cutting corners.
Richard Sullivan, a director for the Institute for Cancer Policy, said: "The concern is we're going to start aping some of what we see as the poor practices of the FDA in terms of accelerated approval.
"If this is about just lowering the bar even more and more, then this is a disaster, because what this is going to do is actually harm British cancer patients, not improve their outcomes."
Related Topics
Brexit, Pharmaceutical industry, Cancer
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM